Applied DNA Sciences Files 8-K on Shareholder Votes

TL;DR

APDN filed an 8-K on Jan 23, 2025, detailing shareholder votes. Governance update.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on January 23, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and governance decisions as of that date.

Why It Matters

This filing provides transparency into key decisions made by Applied DNA Sciences' shareholders, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of shareholder voting matters and does not indicate immediate financial distress or significant operational changes.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• January 23, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 50 Health Sciences Drive Stony Brook, New York 11790 (address) — Principal executive office

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar

Filing Documents

• tm254259d1_8k.htm (8-K) — 23KB
• 0001104659-25-005601.txt ( ) — 191KB
• apdn-20250123.xsd (EX-101.SCH) — 3KB
• apdn-20250123_lab.xml (EX-101.LAB) — 33KB
• apdn-20250123_pre.xml (EX-101.PRE) — 22KB
• tm254259d1_8k_htm.xml (XML) — 3KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On January 23, 2025, Applied DNA Sciences, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, an aggregate of 14,062,557 shares of the Company's common stock ("Common Stock") were present in person or by proxy and entitled to vote, which did not constitute a quorum determined in accordance with the Company's By-Laws, which requires one-third of the Company's issued and outstanding shares of Common Stock. Accordingly, no action was taken with respect to the proposal presented at the Special Meeting, and the Special Meeting was adjourned until February 14, 2025, at 11:00 a.m. in order to permit additional solicitation of stockholders and to allow stockholders additional time to vote on the sole proposal under consideration at the Special Meeting. As previously reported on its Form 8-K filed on October 31, 2024, the Company closed on such date a registered direct public offering and concurrent private placement (the "Offering") of common stock, series C and D common stock purchase warrants (the "Series Warrants") and placement agent warrants ("Placement Agent Warrants", and, with the Series Warrants, the "Private Placement Warrants"). The Private Placement Warrants will only be exercisable upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the "Warrant Stockholder Approval"). Further, pursuant to the terms of the Securities Purchase Agreement entered into in connection with the Offering, since the Company did not obtain Warrant Stockholder Approval at the Special Meeting, it is obligated to call a subsequent stockholder meeting to seek to obtain Warrant Stockholder Approval.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2025 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR